How changes in LINE‑1 'jumping' DNA affect human health

Leveraging natural and directed evolution to dissect the functional consequences of sequence variation in human L1 retrotransposons

NIH-funded research Pacific Northwest Research Institute · NIH-11376348

This work looks at how different versions of LINE‑1 mobile DNA might copy themselves more or less and create mutations that could affect human health.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionPacific Northwest Research Institute NIH-funded
Lab location1 site (Seattle, United States)
Project IDNIH-11376348 on NIH RePORTER

What this research studies

From a patient's point of view, researchers are comparing many naturally occurring human LINE‑1 sequences and testing them in the lab to see which versions can escape the cell's defenses and replicate. They combine computer analyses of past human genomes with lab experiments using a panel of over 130 recent human LINE‑1 variants and directed evolution methods. The team measures how sequence differences change LINE‑1 activity in human cells and how host proteins restrict them. These approaches aim to map which changes lead to genome instability or increased mutational risk.

Who could benefit from this research

Good fit: People with cancers, inherited genome instability syndromes, or conditions suspected to involve increased mobile element activity would be most relevant to the questions this research addresses.

Not a fit: People whose health problems are unrelated to DNA mutations or mobile element activity are unlikely to gain direct benefit from this work in the near term.

Why it matters

Potential benefit: If successful, the findings could clarify how LINE‑1 activity contributes to cancer and other diseases and suggest targets for future diagnostics or interventions.

How similar studies have performed: Previous research has shown that LINE‑1 elements can be active and that host restriction factors evolve to block them, but using large panels of human LINE‑1 variants combined with directed evolution to map functional effects is a newer, more comprehensive approach.

Where this research is happening

Seattle, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Autoimmune DiseasesCancers
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.